Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.5M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$163M |
Are Mainz Biomed Insiders Buying or Selling?
Mainz Biomed (MYNZ) has had no reported insider transactions in the past 90 days. The most recent was Donahue Kevin Michael, who bought 685,000 shares at $1.51 on October 17, 2025.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the MYNZ AI Score. For government officials trading this stock, see MYNZ congressional trading.
Who’s Trading Mainz Biomed Stock?
| Insider | Activity | Trades | Last Trade |
|---|---|---|---|
| Donahue Kevin Michael | Bought $259B | 2 | Oct 17, 2025 |
Recent Mainz Biomed Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Donahue Kevin Michael | Oct 17, 2025 | Buy | 685,000 | $1.51 | $1M |
| Donahue Kevin Michael | Oct 17, 2025 | Buy | 643,850 | $402,000 | $259B |
Frequently Asked Questions: Mainz Biomed Insider Trading
Mainz Biomed insiders have not reported any transactions in the past 90 days.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Donahue Kevin Michael has bought the most MYNZ stock in the last 2 years, with a total value of $259B.
According to our estimates, the total value of insider transactions for Mainz Biomed in the last 2 years is positive, amounting to $259B. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.
